Literature DB >> 23688911

Reduced plakoglobin immunoreactivity in arrhythmogenic cardiomyopathy: methodological considerations.

Maartje Noorman1, Sara Hakim, Angeliki Asimaki, Arnold Vreeker, Harold V M van Rijen, Marcel A G van der Heyden, Nicolaas de Jonge, Roel A de Weger, Richard N W Hauer, Jeffrey E Saffitz, Toon A B van Veen.   

Abstract

BACKGROUND: Arrhythmogenic cardiomyopathy (AC) primarily is considered to be a desmosomal disease with a predominant right ventricular phenotype. Reduced signal intensity for junctional plakoglobin (JUP) at the intercalated disks has been proposed as a marker that contributes to diagnosis of the disease. In this technical study, we investigated how methodology-related differences caused by tissue preservation and antibody dilutions affect an appropriate diagnosis.
METHODS: Autopsy and biopsy material was available from a total of 7 control and 25 AC patients that fulfilled the diagnostic Task Force Criteria as proposed in 2010. Immunohistochemical analysis was performed on cryosections and formalin-fixed material using antibodies against JUP and N-Cadherin.
RESULTS: Immunohistochemistry (1:1000 antibody dilution) on formalin-fixed material showed a reduced signal for JUP in 7/10 AC patients in a bidirectional, double-blinded exchange experiment in which 77% of individuals were correctly classified. Unmasking this disturbed JUP pattern was highly dependent on tissue preservation and antibody dilution since on cryosections the disturbed pattern in patients could only be unmasked at a very strong antibody dilution of 1:100000.
CONCLUSIONS: Reduced immunoreactive signal of JUP at the intercalated disks can be observed in a majority of AC patients. These changes can comparably be detected on both cryo- (74%) and formalin-fixed material (70%) but demand a different, highly defined, and uniformly used approach.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arrhythmogenic cardiomyopathy; Biopsy; Immunohistochemistry; Plakoglobin

Mesh:

Substances:

Year:  2013        PMID: 23688911     DOI: 10.1016/j.carpath.2013.04.002

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  4 in total

1.  Multilevel analyses of SCN5A mutations in arrhythmogenic right ventricular dysplasia/cardiomyopathy suggest non-canonical mechanisms for disease pathogenesis.

Authors:  Anneline S J M Te Riele; Esperanza Agullo-Pascual; Cynthia A James; Alejandra Leo-Macias; Marina Cerrone; Mingliang Zhang; Xianming Lin; Bin Lin; Nara L Sobreira; Nuria Amat-Alarcon; Roos F Marsman; Brittney Murray; Crystal Tichnell; Jeroen F van der Heijden; Dennis Dooijes; Toon A B van Veen; Harikrishna Tandri; Steven J Fowler; Richard N W Hauer; Gordon Tomaselli; Maarten P van den Berg; Matthew R G Taylor; Francesca Brun; Gianfranco Sinagra; Arthur A M Wilde; Luisa Mestroni; Connie R Bezzina; Hugh Calkins; J Peter van Tintelen; Lei Bu; Mario Delmar; Daniel P Judge
Journal:  Cardiovasc Res       Date:  2017-01       Impact factor: 10.787

2.  New Cell Adhesion Molecules in Human Ischemic Cardiomyopathy. PCDHGA3 Implications in Decreased Stroke Volume and Ventricular Dysfunction.

Authors:  Ana Ortega; Carolina Gil-Cayuela; Estefanía Tarazón; María García-Manzanares; José Anastasio Montero; Juan Cinca; Manuel Portolés; Miguel Rivera; Esther Roselló-Lletí
Journal:  PLoS One       Date:  2016-07-29       Impact factor: 3.240

3.  Buccal Mucosa Cells as a Potential Diagnostic Tool to Study Onset and Progression of Arrhythmogenic Cardiomyopathy.

Authors:  Helen E Driessen; Stephanie M van der Voorn; Mimount Bourfiss; Freyja H M van Lint; Ferogh Mirzad; Laila El Onsri; Marc A Vos; Toon A B van Veen
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

4.  Arrhythmogenic cardiomyopathy: pathogenesis, pro-arrhythmic remodelling, and novel approaches for risk stratification and therapy.

Authors:  Stephanie M van der Voorn; Anneline S J M Te Riele; Cristina Basso; Hugh Calkins; Carol Ann Remme; Toon A B van Veen
Journal:  Cardiovasc Res       Date:  2020-07-15       Impact factor: 10.787

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.